Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer

ClinicalTrials.gov ID

NCT07815197

Lead Sponsor

Latin American Cooperative Oncology GroupOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

37Estimated

Last Update Posted

Sep 11, 2026Actual

Start Date

Jan 2027Estimated

Primary Completion Date

Mar 2028Estimated

Completion Date

Oct 2028Estimated

Official Title

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) as Second-line Treatment for Advanced/Metastatic Penile Squamous Cell Carcinoma: PERSEUS TRIAL (LACOG 1924)

Brief Summary

This is a single-arm, Phase 2 clinical trial (PERSEUS TRIAL / LACOG 1924) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (sac-TMT; MK-2870) as a second-line treatment for patients with advanced or metastatic penile cancer. Penile squamous cell carcinoma (PSCC) is a rare and aggressive cancer with limited treatment options once disease progression occurs after initial platinum-based chemotherapy. Sacituzumab tirumotecan is an antibody-drug conjugate (ADC) designed to target TROP-2, a protein frequently expressed at high levels on penile cancer cells. By binding to TROP-2, sac-TMT delivers a anti-cancer payload directly to the tumor cells. All participants in this trial will receive sacituzumab tirumotecan administered via intravenous (IV) infusion every 2 weeks. The main goal of this study is to determine the percentage of patients whose tumors shrink or disappear after receiving sacituzumab tirumotecan (Objective Response Rate).

Detailed Description

Penile squamous cell carcinoma (PSCC) represents a significant unmet medical need, particularly in low- and middle-income regions where the incidence is higher. For patients with disease recurrence or metastasis following first-line platinum-based chemotherapy, standard second-line therapeutic options offer poor response rates and a dismal median overall survival of 4 to 5 months. Recent findings show that over 80% of PSCC cases express high levels of TROP-2, making it a key therapeutic target. Sacituzumab tirumotecan (sac-TMT; MK-2870) is a novel antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody linked to a topoisomerase I inhibitor payload (KL610023). Study Design & Intervention: This is an open-label, multicenter, single-arm Phase 2 trial enrolling 37 adult patients with advanced/metastatic PSCC who experienced disease progression on or after first-line platinum-based chemotherapy. Participants receive sacituzumab tirumotecan at a dose of 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle for up to 8 cycles, or until disease progression, unacceptable toxicity, or consent withdrawal.

Primary Endpoint: Objective Response Rate (ORR), defined as the proportion of participants achieving a confirmed Complete Response (CR) or Partial Response (PR) assessed by the investigator using RECIST v1.1 criteria. Secondary Endpoints:Independent Central Review Objective Response Rate (ORR-ICR) Disease Control Rate (DCR) and Clinical Benefit Rate (CBR at 24 weeks) Duration of Response (DoR) Progression-Free Survival (PFS) and Overall Survival (OS) Safety and toxicity profile (evaluated via CTCAE v5.0) Treatment compliance and post-progression therapies Exploratory Research: Assessment of baseline tumor TROP-2 expression, HPV16 status, ctDNA dynamics, and molecular mechanisms of acquired resistance. Statistical Design: The trial utilizes Simon's two-stage Minimax design (18 participants accrued in Stage 1, expanding to 33 total evaluable participants if $\ge5$ responses are observed). Accounting for a 10% drop-out rate, a total of 37 participants will be enrolled.

• Penile Squamous Cell Carcinoma
• Metastatic Penile Squamous Cell Carcinoma

• Sacituzumab Tirumotecan

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Male

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Histologically- or cytologically confirmed diagnosis of penile squamous cell carcinoma.
• Metastatic or locally advanced disease not amenable to curative intent-therapy (e.g., surgery, radiotherapy, chemoradiotherapy) in the opinion of the investigator.
• Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology (lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions).
• Disease progression on first-line platinum-based chemotherapy for locally advanced/metastatic disease or disease progression within 12 months of (neo) adjuvant chemotherapy completion.
• Male participant at least 18 years of age at the time of providing informed consent.
• Male Participants (Reproductive Potential): If capable of producing sperm, agrees to refrain from donating sperm and use a penile/external condom when having intercourse with a partner of childbearing potential, plus partner use of an additional contraceptive method, during the intervention period and for at least 120 days after the last dose of study intervention.
• The participant (or legally acceptable representative if applicable) provides written informed consent for the study.
• Life expectancy of at least 12 weeks.
• Provide an archival tumor tissue sample or most recently obtained core, incisional, or excisional biopsy of a tumor lesion from any site not previously irradiated; formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides (recommended 22-28 slides).
• Recovery from AEs due to previous anticancer therapies to Grade <=1 or baseline (except for alopecia and vitiligo); participants with endocrine-related AEs adequately treated with hormone replacement therapy are eligible.
• Adequate organ function defined by the laboratory values (specimens collected within 14 days before the start of study intervention):
• Absolute Neutrophil Count (ANC) >= 1,500/uL
• Platelets >= 100,000/uL
• Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
• Measured or calculated Creatinine Clearance > 30 mL/min
• Total Bilirubin <= 1.5 x ULN OR direct bilirubin < ULN for participants with total bilirubin levels > 1.5 x ULN
• AST (SGOT) and ALT (SGPT) <= 2.5 x ULN (<= 5 x ULN for participants with liver metastases)
• Serum Albumin >= 3.0 g/dL
• INR or PT < 1.5 x ULN; aPTT < 1.5 x ULN (unless receiving anticoagulant therapy within therapeutic range)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Willing and able to comply with study procedures, laboratory tests, and other requirements of the study.
• HIV-infected participants are eligible if well-controlled on ART (CD4+ T-cell count >350 cells/mm3, confirmed HIV RNA <50 copies/mL for at least 12 weeks, no AIDS-defining opportunistic infections within past 12 months, and on a stable regimen for at least 4 weeks without strong CYP3A4 inducers/inhibitors).
• Participants with chronic Hepatitis B virus (HBsAg positive) are eligible if received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load before enrollment.
• Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening and completed curative antiviral therapy at least 4 weeks before enrollment.

Exclusion Criteria:

• History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
• Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
• Uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months before first dose (NYHA Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, or QTcF >480 ms).
• Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
• Received prior treatment with a topoisomerase 1 inhibitor-containing ADC.
• Received prior systemic anticancer therapy within 2 weeks before first dose of study intervention.
• Received prior radiotherapy within 2 weeks before first dose, has radiation-related toxicities requiring corticosteroids, and/or has had radiation pneumonitis (palliative radiotherapy <= 2 weeks for non-CNS disease completed at least 7 days before first dose is permitted).
• Received a live or live-attenuated vaccine within 30 days before first dose of study intervention.
• Currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued (washout period required is 2 weeks).
• Currently enrolled on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy.
• Received an investigational agent or used an investigational device within 4 weeks before first dose of study intervention.
• Known additional malignancy that is progressing or has required active treatment within the past 3 years (except adequately treated basal/squamous cell skin cancer, carcinoma in situ, or low-risk early-stage prostate cancer).
• History of CNS metastases and/or carcinomatous meningitis.
• Active infection requiring systemic therapy within 4 weeks prior to first dose of study treatment (except permitted treated HIV, HBV, HCV).
• Severe hypersensitivity (Grade >=3) to study intervention, any of its excipients, and/or to another biologic therapy.
• Major surgery or significant traumatic injury within 4 weeks before first dose, or anticipation of need for major surgery during treatment.
• History of (noninfectious) pneumonitis/interstitial lung disease requiring steroids or current pneumonitis/interstitial lung disease.
• Any condition, therapy, laboratory abnormality, or circumstances that might confound study results or interfere with compliance in the opinion of the investigator.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Latin American Cooperative Oncology GroupOTHER

Collaborators

Merck Sharp & Dohme LLCINDUSTRY

flaviosbitencourt@gmail.com+5585999547790

cristiany.jslima@hsl.org.br+5561999932784

adylameira@gmail.com+5591981444631

anapaula.costa@liga.org.br+558440095595

gustavo.escott@santacasa.org.br+555132148107

pedro.santos@hospitaldeamor.com.br+551733216637

camila.lollo@bp.org.br+551135056693

• Sac-TMT in Vaginal and Vulvar Cancers

  NCT07804966

  Not yet recruitingInterventionalPhase 2Updated Sep 4, 2026
• Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

  NCT06049212

  Active, not recruitingInterventionalPhase 1Updated Sep 2, 2026
• A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

  NCT07108816

  Not yet recruitingInterventionalPhase 2Updated Aug 7, 2025
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176

  RecruitingInterventionalPhase 3Updated Sep 3, 2026
• Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

  NCT07244874

  Not yet recruitingInterventionalPhase 2Updated Nov 24, 2025
• A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180

  Active, not recruitingInterventionalPhase 3Updated Aug 28, 2026